欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (3): 278-281.

• 研究原著 • 上一篇    下一篇

灯盏花素对脑缺血再灌注损伤的保护作用和治疗时间窗

何蔚1, 陈汇, 曾繁典   

  1. 华中科技大学同济医学院临床药理研究所, 武汉 430030, 湖北; 1赣南医学院药理教研室, 赣州 341000, 江西
  • 收稿日期:2002-12-28 修回日期:2003-02-25 出版日期:2003-06-26 发布日期:2020-11-25
  • 通讯作者: 曾繁典, 男, 教授, 博士生导师, 中国药理学会副理事长, 研究方向:临床药理和心血管药理。Tel:027-83630652 Fax;027-83622308 E-mail:fdzeng@mails.tjmu.edu.cn
  • 作者简介:何蔚, 男, 讲师, 研究方向:临床药理和心脑血管药理。Tel:027-83692009 E-mail:hewei8286291@yahoo.com.cn

Protective effect of breviscapine on cerebral ischemia-reperfusion injury and therapeutic window of opportunity

HE Wei1, CHEN Hui, ZENG Fan-Dian   

  1. Institute of Clinical Pharmacology, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, Hubei; 1Department of Pharmacology, Jiangxi Gannan Medical College, Ganzhou 341000, Jiangxi
  • Received:2002-12-28 Revised:2003-02-25 Online:2003-06-26 Published:2020-11-25

摘要: 目的: 研究灯盏花素对脑缺血再灌注损伤的保护作用和治疗时间窗。方法: 线栓法制备大鼠大脑中动脉阻断(MCAO)局灶性脑缺血模型, 缺血前给予灯盏花素50、75 mg·kg-1, ig, qd ×7 d。末次给药1 h 制备MCAO 模型, 缺血2 h, 再灌注3 h, 评价神经功能状态、脑水肿和脑梗死范围;放免法测定血清IL-8 的含量和分光光度法测定脑组织中伊文思蓝(EB)的含量;灯盏花素的治疗时间窗研究, 采用MCAO 局灶性脑缺血2 h, 再灌注24 h 模型, 分别在缺血开始3、4.5、6 h 腹腔注射灯盏花素75 mg·kg-1,再灌注22 h, 重复给药1 次, 再灌注24 h, 评价神经功能状态、脑水肿和脑梗死范围。结果: 灯盏花素75 mg·kg-1 , ig, qd ×7 d 能改善大鼠脑缺血再灌注后神经功能评分, 减轻脑水肿和减少脑梗死范围, 降低血清IL-8 的含量和降低大鼠脑组织中EB 的含量;在缺血后3 h 治疗用药, 能有效改善大鼠脑缺血再灌注后神经功能评分, 减轻脑水肿和减少脑梗死范围, 4.5 h 开始用药, 疗效下降, 6 h 开始用药, 上述各指标有下降趋势, 但无统计学差异。结论: 灯盏花素对脑缺血再灌注损伤有保护作用, 有效治疗时机在缺血4.5 h 内。

关键词: 药理学, 灯盏花素, 脑缺血, 再灌注损伤, 血脑屏障, 伊文思蓝, 白介素-8, 治疗时间窗

Abstract: AIM: To investigate the protective effect of breviscapine (Bre)on cerebral ischemia-reperfusion injury and the therapeutic window of opportunity. METHODS: Focal cerebral ischemia-reperfusion models in rats were induced by the transient occlusion of the middle cerebral artery for 2 h, followed by reperfusion for 3 h, and the animals were administered Bre 50, and 75mg·kg -1, ig, qd ×7 d before transient MCAO.After the reperfusion, the influence of Bre on neurological deficit score, infarct size and brain edema were observed.The serum concentration of IL-8 was detected with radioimmunoassay (RIA), and the brain tissue EB content was examined with spectrophotometer.For the therapeutic window of opportunity, the MCAO model was induced by transient occlusion for 2 h and reperfusion for 24 h.The drugs were administered at 3 h, 4.5 h and 6 h after the onset of ischemia, respectively, and the second administration was at 22 h after reperfusion.The neurological deficit score, infarct size and brain edema were examined. RESULTS: Bre 75 mg·kg -1, ig, qd ×7 d before MCAO significantly reduced the neurological deficit score, the infarct size, and brain edema.The serum content of IL-8 and the brain tissue EB content decreased after ischemia-reperfusion injury.The administration of Bre beginning at 3 h after the onset of ischemia significantly reduced neurological deficit score, infarct size and brain edema, but starting treatment at 4.5 h after onset of ischemia, the neuroprotective effects decreased, and starting at 6 h after onset of ischemia did not result in significant reduction of the above indexes for brain tissue. CONCLUSION: Bre has protective effects on cerebral ischemia-reperfusion injury. The therapeutic window of opportunity of Bre in transient focal cerebral ischemia injury is no more than 4.5 h after onset of ischemia.

Key words: pharmacology, breviscapine, cerebral ischemia, reperfusion injury, blood brain barrier, Evens blue, interleukin-8, therapeutic window of opportunity

中图分类号: